RxDoctor Payments Data

Punuru Reddy, MD

Internal Medicine · Decatur, ALNPI 1760541197

Payments from drug & device makers

$5,972in general payments, 2019–2025

Across 379 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$613
  • Merck$425
  • AbbVie$408
  • Pfizer$381
  • Astellas Pharma US Inc$379
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$5,46491%
  • Education$4498%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,972 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$336,366
Medicare patients
1,428
Services billed
6,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide12$510,757
Trelegy ElliptaFluticasone/Umeclidin/Vilanter206$189,927
EliquisApixaban178$157,195
XareltoRivaroxaban168$148,290
OzempicSemaglutide115$144,850
RybelsusSemaglutide133$143,036
JardianceEmpagliflozin79$102,709
EntrestoSacubitril/Valsartan76$67,621
MounjaroTirzepatide33$58,198
JanuviaSitagliptin Phosphate41$44,909
FarxigaDapagliflozin Propanediol59$44,765
Tresiba Flextouch U-100Insulin Degludec37$26,224
LinzessLinaclotide31$25,549
Lantus SolostarInsulin Glargine,hum.Rec.Anlog228$25,418
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/726$23,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex, Trintellix$221$517,42623 claims
Novo NordiskOzempic, Rybelsus$1,012$287,886248 claims
GSKTrelegy Ellipta, Breo Ellipta$613$199,700230 claims
PfizerEliquis$381$157,195178 claims
Johnson & JohnsonXarelto$96$148,290168 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$58$133,187110 claims
NovartisEntresto$152$67,62176 claims
Lilly USA, LLCMounjaro$151$58,19833 claims
MerckJanuvia$425$44,90941 claims
AstraZenecaFarxiga$179$44,76559 claims
AbbVieLinzess, Creon$408$41,71157 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$9,455800 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →